Chembio Diagnostics Reports First Quarter 2020 Financial Results

May 4, 2020

HAUPPAUGE, N.Y., May 04, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2020.

Recent Accomplishments & Highlights

  • Attained FDA Emergency Use Authorization for the DPP COVID-19 IgM/IgG System serological test
    • Announced the U.S. launch and shipments to customers of the DPP COVID-19 System
    • Selected by Stony Brook Medicine as the testing solution to identify COVID-19 survivors for study on COVID-19 convalescent plasma therapy
    • Received a $4.0 million purchase order from Bio-Manguinhos for our DPP COVID-19 System
  • Completed the reproducibility study and submitted data to the FDA for our DPP HIV-Syphilis test
  • Appointed Richard Eberly as President and Chief Executive Officer and director and appointed Gail Page as Executive Chair of the Board
  • Achieved total revenue of $6.9 million and product revenue of $5.7 million

“During the first quarter, we refocused our business strategy to address the escalating need for COVID-19 diagnostic tests. In a short period of time, we developed a COVID-19 serological testing system, received FDA Emergency Use Authorization and began shipping tests to customers in the United States and Brazil in April. Our differentiated testing system offers numerical discrete detection of both IgM and IgG antibodies in approximately 15 minutes from a fingerstick. Then, in approximately 15 seconds, the DPP COVID-19 System reads the test to provide numerical results using the portable Micro Reader analyzers that are engineered and produced by our wholly owned subsidiary in Germany. Numerical results reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many other serological tests,” said Gail Page, Chembio’s Executive Chair of the Board. “We are proud to be serving the needs of clinicians and the broader healthcare community in this time of crisis.”

“It has been an extremely productive first few weeks in my new role as CEO. Amid these challenging circumstances, the skill and hard work of this team has enabled a successful strategic pivot as we prioritize manufacturing and commercialization of our DPP COVID-19 System,” said Richard Eberly, Chembio’s Chief Executive Officer. “Through efficient use of our resources and technical ability, we are scaling production of these tests due to the strong demand we are experiencing. We believe the features and benefits offered by our DPP COVID-19 System will make it a preferred solution.”

First Quarter 2020 Financial Results
Total revenue for the first quarter of 2020 was $6.9 million, a decrease of 20% compared to the prior year period. Net product sales for the first quarter of 2020 were $5.7 million, a decrease of 14% compared to the prior year period. License and royalty revenue together with R&D and grant revenue for the first quarter of 2020 was $1.1 million, a decrease of 40% compared to the prior year period.

Gross product margin for the first quarter of 2020 was $1.3 million, compared to $1.6 million for the prior year period. Gross product margin percentage for the first quarter of 2020 was 23.5%, compared to 24.3% for the prior year period, a decrease resulting primarily from unfavorable average selling prices due to geographic mix.

Research and development expenses decreased by $0.3 million, or 12%, for the first quarter of 2020 compared to the prior year period. Selling, general and administrative expenses increased by $0.5 million, or 12%, for the first quarter of 2020 compared to the prior year period, with $0.4 million of the increase representing severance and related costs and acquisition costs, for a net increase of $0.1 million, or 4%.

Net loss for the first quarter of 2020 was $5.0 million, or $(0.29) per diluted share, compared to a net loss of $2.8 million, or $(0.16) per diluted share, for the prior year period. 

Cash and cash equivalents as of March 31, 2020 totaled $11.2 million.

Conference Call
Chembio will host a conference call today beginning at 4:30 pm ET to discuss its financial results and recent business highlights. Investors interested in listening to the call may do so by dialing 844-602-0380 from the United States or 862-298-0970 from outside the United States. To listen to a live webcast of the call, please visit the Investor Relations section of Chembio's website at www.chembio.com. Following the call, a replay will be available on the Investor Relations section of Chembio’s website for 90 days. A telephone replay will be available until 4:30 pm ET on May 18, 2020 by dialing 877-481-4010 from the United States or 919-882-2331 from outside the United States and using the conference ID: 34409.

About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases including COVID-19, sexually transmitted disease and fever and tropical disease. Chembio’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies and consumers. Learn more at www.chembio.com.

Forward-Looking Statements
Statements contained in this release that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of Chembio and its management. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to: the impact to our business, our suppliers and our customers of the COVID-19 pandemic and the actions taken to combat the COVID-19 pandemic;  the ability of Chembio to maintain existing, and timely obtain additional, regulatory approvals, particularly for our DPP COVID-19 System; and the risks of doing business with foreign governmental entities, including geopolitical, international and other challenges as well as potential material adverse effects of tariffs and other changes in U.S. trade policy. Chembio undertakes no obligation to publicly update forward-looking statements in this release to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to the forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's public filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and its subsequent Quarterly Reports on Form 10-Q, particularly under the heading “Risk Factors.” You should interpret many of the risks identified in these reports as being heightened as a result of the ongoing and numerous adverse impacts of the COVID-19 pandemic.

DPP is Chembio’s registered trademark. For convenience, this trademark appears in this release without ® symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.

Philip Taylor
Gilmartin Group
(415) 937-5406


  For the three months ended
  March 31, 2020   March 31, 2019
Net product revenue $ 5,716,593     $ 6,624,285  
R&D and grant revenue   907,687       1,701,789  
License and royalty revenue   235,304       216,191  
TOTAL REVENUES   6,859,584       8,542,265  
Cost of product revenue   4,374,442       5,011,636  
Research and development expenses   1,958,853       2,217,632  
Selling, general and administrative expenses   4,156,641       4,013,071  
Severance and related costs   723,118       -  
Acquisition costs   63,497       395,612  
    11,276,551       11,637,951  
LOSS FROM OPERATIONS   (4,416,967 )     (3,095,686 )
Interest (expense) income, net   (662,141 )     6,684  
LOSS BEFORE INCOME TAXES   (5,079,108 )     (3,089,002 )
Income tax (benefit)   (79,559 )     (272,469 )
NET LOSS $ (4,999,549 )   $ (2,816,533 )
Basic and Diluted loss per share $ (0.29 )   $ (0.16 )
Weighted-average number of shares outstanding, basic   17,197,301       17,166,459  
Weighted-average number of shares outstanding, diluted     17,197,301       17,166,459  


March 31, 2020
  December 31, 2019
- ASSETS -      
Cash and cash equivalents $ 11,238,017     $ 18,271,352  
Accounts receivable, net   4,877,842       3,661,325  
Inventories, net   10,930,159       9,598,030  
Prepaid expenses and other current assets   798,228       693,013  
TOTAL CURRENT ASSETS   27,844,246       32,223,720  
FIXED ASSETS:              
Property, plant and equipment, net   6,659,279       5,933,569  
Finance lease right-of-use asset   226,305       210,350  
TOTAL FIXED ASSETS, net   6,885,584       6,143,919  
OTHER ASSETS:              
Operating lease right-of-use asset, net   6,785,668       7,030,744  
Intangible assets, net   3,655,858       3,914,352  
Goodwill   5,493,045       5,872,690  
Deposits and other assets   528,261       543,539  
TOTAL ASSETS $ 51,192,662     $ 55,728,964  
Accounts payable and accrued liabilities $ 6,536,134     $ 5,526,243  
Deferred revenue   543,345       125,000  
Note payable   112,928       180,249  
Finance lease liabilities   47,192       41,894  
Operating lease liabilities   766,896       568,294  
TOTAL CURRENT LIABILITIES   8,006,495       6,441,680  
OTHER LIABILITIES:              
Long-term operating lease liabilities   6,770,005       6,969,603  
Long-term finance lease liabilities   184,095       171,953  
Long-Term debt, less current portion, and debt discount and issuance costs   17,771,268       17,644,149  
Deferred tax liability   327,542       466,326  
TOTAL LIABILITIES   33,059,405       31,693,711  
Preferred stock – 10,000,000 shares authorized, none outstanding   -       -  
Common stock - $0.01 par value; 100,000,000 shares authorized, 17,327,235 shares and 17,733,617 shares issued at March 31, 2020 and December 31, 2019, respectively   173,272       177,335  
Additional paid-in capital   95,543,043       95,433,077  
Accumulated deficit   (76,584,552 )     (71,585,003 )
Treasury Stock, 31,486 shares at cost   (145,056 )     -  
Accumulated other comprehensive (loss) income   (853,450 )     9,844  
TOTAL STOCKHOLDERS’ EQUITY   18,133,257       24,035,253  
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 51,192,662     $ 55,728,964  


  For the three months ended
  March 31, 2020   March 31, 2019
Net cash used in operating activities $ (5,651,960 )   $ (4,754,878 )
Net cash used in investing activities   (1,078,271 )     (577,472 )
Net cash provided by financing activities   (223,290 )     (29,930 )
Effect of exchange rate changes on cash   (79,814 )     208,407  
DECREASE IN CASH AND CASH EQUIVALENTS   (7,033,335 )     (5,153,873 )
Cash and cash equivalents - beginning of the period   18,271,352       12,524,551  
Cash and cash equivalents - end of the period $ 11,238,017     $ 7,370,678  



Source: Chembio Diagnostics, Inc.